Skip to main content
. 2016 Dec 14;10:2531–2541. doi: 10.2147/PPA.S119570

Figure 1.

Figure 1

(A) Percentage of patients receiving pharmacotherapy for acromegaly; (B) percentage of patients receiving combination therapies.

Note: *Other refers to any agent(s) other than a somatostatin analog (eg, pegvisomant and cabergoline).